GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » Piotroski F-Score

Aarti Drugs (BOM:524348) Piotroski F-Score : 4 (As of Apr. 29, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aarti Drugs has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Aarti Drugs's Piotroski F-Score or its related term are showing as below:

BOM:524348' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 4

During the past 13 years, the highest Piotroski F-Score of Aarti Drugs was 9. The lowest was 2. And the median was 6.


Aarti Drugs Piotroski F-Score Historical Data

The historical data trend for Aarti Drugs's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs Piotroski F-Score Chart

Aarti Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 9.00 8.00 5.00 4.00

Aarti Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.00 - - -

Competitive Comparison of Aarti Drugs's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was ₹1,663 Mil.
Cash Flow from Operations was ₹1,342 Mil.
Revenue was ₹27,161 Mil.
Gross Profit was ₹4,935 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (22079.584 + 24213.982) / 2 = ₹23146.783 Mil.
Total Assets at the begining of this year (Mar22) was ₹22,080 Mil.
Long-Term Debt & Capital Lease Obligation was ₹2,051 Mil.
Total Current Assets was ₹14,923 Mil.
Total Current Liabilities was ₹9,330 Mil.
Net Income was ₹2,050 Mil.

Revenue was ₹24,886 Mil.
Gross Profit was ₹5,037 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (17660.136 + 22079.584) / 2 = ₹19869.86 Mil.
Total Assets at the begining of last year (Mar21) was ₹17,660 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,404 Mil.
Total Current Assets was ₹13,934 Mil.
Total Current Liabilities was ₹9,401 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aarti Drugs's current Net Income (TTM) was 1,663. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aarti Drugs's current Cash Flow from Operations (TTM) was 1,342. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=1663.088/22079.584
=0.07532243

ROA (Last Year)=Net Income/Total Assets (Mar21)
=2050.386/17660.136
=0.1161025

Aarti Drugs's return on assets of this year was 0.07532243. Aarti Drugs's return on assets of last year was 0.1161025. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Aarti Drugs's current Net Income (TTM) was 1,663. Aarti Drugs's current Cash Flow from Operations (TTM) was 1,342. ==> 1,342 <= 1,663 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=2050.804/23146.783
=0.08859996

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=1403.782/19869.86
=0.07064881

Aarti Drugs's gearing of this year was 0.08859996. Aarti Drugs's gearing of last year was 0.07064881. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=14923.49/9329.78
=1.59955433

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=13933.728/9400.581
=1.48221988

Aarti Drugs's current ratio of this year was 1.59955433. Aarti Drugs's current ratio of last year was 1.48221988. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Aarti Drugs's number of shares in issue this year was 92.6. Aarti Drugs's number of shares in issue last year was 92.6. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4934.549/27160.536
=0.18168084

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5036.626/24886.458
=0.2023842

Aarti Drugs's gross margin of this year was 0.18168084. Aarti Drugs's gross margin of last year was 0.2023842. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=27160.536/22079.584
=1.23011992

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=24886.458/17660.136
=1.40918836

Aarti Drugs's asset turnover of this year was 1.23011992. Aarti Drugs's asset turnover of last year was 1.40918836. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aarti Drugs has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Aarti Drugs  (BOM:524348) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Aarti Drugs Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs (BOM:524348) Business Description

Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400 022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm generates the majority of its revenue from India.

Aarti Drugs (BOM:524348) Headlines

No Headlines